Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis.

Abstract

Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.

• Authors: Luke A Garske, Scott C Bell
• Journal: Chest (Chest) Vol. 121 Issue 4 Pg. 1363-4 (Apr 2002) ISSN: 0012-3692 [Print] United States
• PMID: 11948079 (Publication Type: Case Reports, Journal Article)

Chemical References

• Diphosphonates
• Pamidronate

Topics

• Adult
• Ankle (diagnostic imaging)
• Cystic Fibrosis (diagnostic imaging, drug therapy)
• Diphosphonates (therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Osteoarthropathy, Secondary Hypertrophic (diagnostic imaging, drug therapy)
• Osteoclasts (drug effects)
• Pamidronate
• Radiography